Skip to Content

Phase 3 Data on VIVUS' Qnexa to Be Presented at 17th European Congress on Obesity

Update: Qsymia (phentermine/topiramate) Now FDA Approved - July 17, 2012

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Apr 30, 2009 - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that data from the phase 3 EQUATE trial (OB-301) of Qnexa™ in obese patients will be presented at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands. Qnexa, an investigational new drug for the treatment of obesity, simultaneously addresses both appetite and satiety – the two main mechanisms that impact eating behavior.

Efficacy and safety data from a 28-week, phase 3 obesity trial evaluating Qnexa in 756 patients at 32 sites will be presented by Donna H. Ryan, MD, Associate Executive Director for Clinical Research, Pennington Biomedical Research Center, Baton Rouge, LA. Dr. Ryan's presentation, entitled “Weight Loss at 6 Months with VI-0521 Treatment,” [HT:PO22] will occur on Thursday, May 7, 2009 at 1:30 P.M., local time, during the Hot Topic Poster session.

"There is an urgent need for new, more effective, safe treatment options among the millions of people worldwide battling obesity and associated health risks including high blood pressure, high cholesterol and diabetes,” commented Leland Wilson, president and chief executive officer of VIVUS. “In clinical studies to date, Qnexa has demonstrated significant weight loss and other health benefits. The EQUATE data builds upon a growing body of evidence affirming the potential role this novel, proprietary treatment may play for obese patients and for the physicians treating them. We look forward to presenting these new data at this year's European Congress on Obesity, and sharing new insights with the medical community.”


VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa™, is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist™, its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit

Posted: April 2009